Systemic thrombolysis in a patient with intermediate-high risk pulmonary embolism: a case report
S. K. Kononov,
O. V. Soloviev,
D. E. Nazarov,
I. S. Metelev,
E. V. Grebeneva,
N. S. Karpunina,
D. A. Khomyakov,
T. P. Ovsyannikova https://doi.org/10.15829/1560-4071-2025-6688
EDN: QJZANS
Abstract
This article presents a case of systemic thrombolytic therapy in a patient with intermediate-high risk pulmonary embolism (PE). Several randomized clinical trials of thrombolytic therapy in this patient population are currently underway worldwide, but the related evidence base remains insufficient. The efficacy and safety of thrombolytic therapy are demonstrated. The complexity and lack of definitive criteria for deciding on thrombolysis in real-world clinical practice are emphasized. We noted the importance of an individualized assessment of the clinical situation.
About the Authors
S. K. Kononov
Center for Cardiology and Neurology;
Kirov State Medical University
Russian Federation
Russian Federation
Ivana Popova str., 41, Kirov, 610014;
Vladimirskaya str., 112, Kirov, 610027
O. V. Soloviev
Center for Cardiology and Neurology;
Kirov State Medical University
Ivana Popova str., 41, Kirov, 610014;
Vladimirskaya str., 112, Kirov, 610027
D. E. Nazarov
Center for Cardiology and Neurology;
Kirov State Medical University
Ivana Popova str., 41, Kirov, 610014;
Vladimirskaya str., 112, Kirov, 610027
I. S. Metelev
Center for Cardiology and Neurology;
Kirov State Medical University
Ivana Popova str., 41, Kirov, 610014;
Vladimirskaya str., 112, Kirov, 610027
E. V. Grebeneva
Center for Cardiology and Neurology;
Kirov State Medical University
Ivana Popova str., 41, Kirov, 610014;
Vladimirskaya str., 112, Kirov, 610027
N. S. Karpunina
E. A. Wagner Perm State Medical University
Petropavlovskaya str., 26, Perm, 614990
D. A. Khomyakov
Center for Cardiology and Neurology
Ivana Popova str., 41, Kirov, 610014
T. P. Ovsyannikova
Center for Oncology and Medical Radiology
Stroiteley prospekt, 23, Kirov, 610045
References
1. Goldhaber SZ, Visani L, De Rosa M, et al. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 1999;353:1386-9. doi:10.1016/s0140-6736(98)07534-5.
2. Becattini C, Agnelli G, Lankeit M, et al. Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model. Eur Respir J. 2016;48:780-6. doi:10.1183/13993003.00024-2016.
3. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41:543-603. doi:10.1093/eurheartj/ehz405.
4. Giri J, Sista AK, Weinberg I, et al. Interventional therapies for acute pulmonary embolism: current status and principles for the development of novel evidence: a scientific statement from the American Heart Association. Circulation. 2019;140:e774-e801. doi:10.1161/CIR.0000000000000707.
5. Chatterjee S, Chakraborty A, Weinberg I, et al. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. JAMA. 2014;311:2414-21. doi:10.1001/jama.2014.5990.
6. Secemsky E, Chang Y, Jain CC, et al. Contemporary management and outcomes of patients with massive and submassive pulmonary embolism. Am J Med. 2018;131:1506-14. doi:10.1016/j.amjmed.2018.07.035.
7. Meyer G, Vicaut E, Danays T, et al. PEITHO Investigators. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med. 2014;370(15):1402-11. doi:10.1056/NEJMoa1302097.
8. Sanchez O, Charles-Nelson A, Ageno W, et al. PEITHO-3 Investigators. Reduced-Dose Intravenous Thrombolysis for Acute Intermediate-High-risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism International THrOmbolysis (PEITHO)-3 trial. Thromb Haemost. 2022;122(5):857-66. doi:10.1055/a-1653-4699.
9. Klok FA, Piazza G, Sharp ASP, et al. Ultrasound-facilitated, catheter-directed thrombolysis vs anticoagulation alone for acute intermediate-high-risk pulmonary embolism: Rationale and design of the HI-PEITHO study. Am Heart J. 2022;251:43-53. doi:10.1016/j.ahj.2022.05.011.
10. Simakova MA, Parkhomenko SI, Lapshin KB, et al. Efficacy of transcatheter low-dose thrombolysis in patients with intermediate-high risk pulmonary embolism. Study rationale and design. Russian Journal of Cardiology. 2025;30(3):6060. (In Russ.) doi:10.15829/1560-4071-2025-6060. EDN: HDSXKQ.
11. Barco S, Vicaut E, Klok FA, et al. PEITHO Investigators. Improved identification of thrombolysis candidates amongst intermediate-risk pulmonary embolism patients: implications for future trials. Eur Respir J. 2018;51(1):1701775. doi:10.1183/13993003.01775-2017.
12. Zhang RS, Yuriditsky E, Zhang P, et al. Composite Pulmonary Embolism Shock Score and Risk of Adverse Outcomes in Patients With Pulmonary Embolism. Circ Cardiovasc Interv. 2024;17(8):e014088. doi:10.1161/CIRCINTERVENTIONS.124.014088.
13. Götzinger F, Lauder L, Sharp ASP, et al. Interventional therapies for pulmonary embolism. Nat Rev Cardiol. 2023;20(10):670-84. doi:10.1038/s41569-023-00876-0.
14. Jara-Palomares L, Jiménez D, Bikdeli B, et al. RIETE investigators; RIETE Steering Committee Members: Members of the RIETE Group: Derivation and validation of a clinical prediction rule for thrombolysis-associated major bleeding in patients with acute pulmonary embolism: the BACS score. Eur Respir J. 2020;56(6):2002336. doi:10.1183/13993003.02336-2020.
15. Chatterjee S, Weinberg I, Yeh RW, et al. Risk factors for intracranial haemorrhage in patients with pulmonary embolism treated with thrombolytic therapy Development of the PE-CH Score. Thromb Haemost. 2017;117(2):246-51. doi:10.1160/TH16-07-0588.
16. Kirienko AI, Leontyev SG, Yarovaya EB, et al. Non-immunogenic staphylokinase — a thrombolytic agent in the treatment of massive pulmonary embolism: results of the FORPE clinical trial. Russian Journal of Cardiology. 2024;29(11):6157. (In Russ.) doi:10.15829/1560-4071-2024-6157.
17. Kirienko AI, Leontyev SG, Tereschenko SN, et al.; FORPE study group. Non-immunogenic recombinant staphylokinase versus alteplase for patients with massive pulmonary embolism: a randomized open-label, multicenter, parallel-group, non-inferiority trial, FORPE. J Thromb Haemost. 2025;23(2):657-67. doi:10.1016/j.jtha.2024.09.035.
18. Leontyev SG, Yarovaya EB, Kutsenko VA, et al. The safety of non-immunogenic recombinant staphylokinase in elderly patients with massive pulmonary embolism: a randomized clinical trial FORPE. Health Sci Rep. 2025;8(5):e70826. doi:10.1002/hsr2.70826.
19. Tereshchenko SN, Yarovaya EB, Leontiev SG, et al. Non-immunogenic staphylokinase in patients with massive intermediate-high risk pulmonary embolism: protocol of the FORPE-2 multicenter, double-blind, randomized, placebo-controlled trial. Russian Journal of Cardiology. 2025;30(2):6291. (In Russ.) doi:10.15829/1560-4071-2025-6291. EDN: UEUTUR.
20. Konstantinides SV, Vicaut E, Danays T, et al. Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary Embolism. J Am Coll Cardiol. 2017;69(12):1536-44. doi:10.1016/j.jacc.2016.12.039.
21. Klok FA, Ageno W, Ay C, et al. Optimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with the European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology, endorsed by the European Respiratory Society. Eur Heart J. 2022;43(3):183-9. doi:10.1093/eurheartj/ehab816.
22. Valerio L, Mavromanoli AC, Barco S, et al. FOCUS Investigators. Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study. Eur Heart J. 2022;43(36):3387-98. doi:10.1093/eurheartj/ehac206.
23. Steiner D, Nopp S, Weber B, et al. The post-VTE functional status scale for assessment of functional limitations in patients with venous thromboembolism: Construct validity and responsiveness in a prospective cohort study. Thromb Res. 2023;221:1-6. doi:10.1016/j.thromres.2022.11.006.
Review
For citations:
Kononov S.K., Soloviev O.V., Nazarov D.E., Metelev I.S., Grebeneva E.V., Karpunina N.S., Khomyakov D.A., Ovsyannikova T.P. Systemic thrombolysis in a patient with intermediate-high risk pulmonary embolism: a case report. Russian Journal of Cardiology. 2025;30(12):6688. (In Russ.) https://doi.org/10.15829/1560-4071-2025-6688. EDN: QJZANS
Views:
50
JATS XML
Email this article 